The University of Southampton
University of Southampton Institutional Repository

Monoamine oxidase inhibitors (MAOIs) for trichotillomania: a case series

Monoamine oxidase inhibitors (MAOIs) for trichotillomania: a case series
Monoamine oxidase inhibitors (MAOIs) for trichotillomania: a case series

Purpose/Background Despite several decades of research, there are no US Food and Drug Administration-approved medications for trichotillomania or medications generally approved in other geographical jurisdictions. Monoamine oxidase inhibitors show efficacy in the treatment of depression and some possible promise for obsessive compulsive disorder. Methods/Procedures We present new data from a case series collected in a specialty clinical practice over a 4-year period. Findings/Results In 5 treatment-resistant patients whose trichotillomania had not improved with at least 1 course of cognitive behavior therapy and trials of n-acetyl cysteine, an antipsychotic, and a serotonin selective reuptake inhibitor, 2 had marked clinical improvement (>40% improvement) on phenelzine, 1 improved on tranylcypromine, and 2 showed no improvement (<10%) on phenelzine. In 2 of the 3 patients who experienced improvement, there was co-occurring depression. Implications/Conclusions Monoamine oxidase inhibitors in trichotillomania may deserve large-scale randomized controlled trials, particularly in specialist settings where first-line interventions have proven inadequate to manage severe symptoms.

MAOI, pharmacotherapy, trichotillomania
0271-0749
149-151
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Chamberlain, Samuel
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Chamberlain, Samuel
8a0e09e6-f51f-4039-9287-88debe8d8b6f

Grant, Jon E. and Chamberlain, Samuel (2023) Monoamine oxidase inhibitors (MAOIs) for trichotillomania: a case series. Journal of Clinical Psychopharmacology, 43 (2), 149-151. (doi:10.1097/jcp.0000000000001654).

Record type: Article

Abstract

Purpose/Background Despite several decades of research, there are no US Food and Drug Administration-approved medications for trichotillomania or medications generally approved in other geographical jurisdictions. Monoamine oxidase inhibitors show efficacy in the treatment of depression and some possible promise for obsessive compulsive disorder. Methods/Procedures We present new data from a case series collected in a specialty clinical practice over a 4-year period. Findings/Results In 5 treatment-resistant patients whose trichotillomania had not improved with at least 1 course of cognitive behavior therapy and trials of n-acetyl cysteine, an antipsychotic, and a serotonin selective reuptake inhibitor, 2 had marked clinical improvement (>40% improvement) on phenelzine, 1 improved on tranylcypromine, and 2 showed no improvement (<10%) on phenelzine. In 2 of the 3 patients who experienced improvement, there was co-occurring depression. Implications/Conclusions Monoamine oxidase inhibitors in trichotillomania may deserve large-scale randomized controlled trials, particularly in specialist settings where first-line interventions have proven inadequate to manage severe symptoms.

Text
TTM-MAOI-11-4-22-clean copy - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (40kB)

More information

e-pub ahead of print date: 26 January 2023
Published date: 1 April 2023
Additional Information: Funding Information: J.E.G. has received research grants from Janssen and Biohaven Pharmaceuticals. He receives yearly compensation from Springer Publishing for acting as editor-in-chief of the Journal of Gambling Studies and has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. S.R.C.'s involvement in this research was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z). He receives a stipend from Elsevier for editorial work. For the purpose of open access, the author has applied a CC BY public copyright license to any author accepted manuscript version arising from this submission. Publisher Copyright: © 2023 Wolters Kluwer Health, Inc.
Keywords: MAOI, pharmacotherapy, trichotillomania

Identifiers

Local EPrints ID: 477332
URI: http://eprints.soton.ac.uk/id/eprint/477332
ISSN: 0271-0749
PURE UUID: 8ece7d1e-8b60-4989-acec-9580896b6a4b
ORCID for Samuel Chamberlain: ORCID iD orcid.org/0000-0001-7014-8121

Catalogue record

Date deposited: 05 Jun 2023 16:34
Last modified: 30 Aug 2024 02:00

Export record

Altmetrics

Contributors

Author: Jon E. Grant
Author: Samuel Chamberlain ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×